Genetic SNP Weighting for Personalized Cannabinoid Regimens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for determining cannabinoid treatment regimens are inefficient and costly, often taking months and thousands of dollars to find the appropriate dosage and ratio for a user's condition, without considering individual genetic variations that impact response to cannabinoids.
Innovation Solution
A method and system utilizing patient DNA information to determine personalized cannabinoid treatment regimens by obtaining base values for cannabinoids based on single nucleotide polymorphisms (SNPs), modifying these values with weighting factors derived from genetic testing, and adjusting dosages and ratios to account for individual genetic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional trial-and-error methods are used to determine cannabinoid treatment regimens, then treatment efficacy may eventually be achieved, but the process takes months and thousands of dollars in time and cost
Solution Approach 1:
The patent performs genetic testing and SNP analysis before initiating cannabinoid treatment to pre-determine the optimal dosage and ratio. By obtaining the patient's genetic profile in advance and using it to calculate personalized treatment parameters, the system eliminates the need for months of trial-and-error adjustments, directly resolving the contradiction between treatment accuracy and time investment
Solution Approach 2:
The patent introduces genetic markers and SNP profiles as intermediary variables that mediate between the patient's genetic makeup and the optimal cannabinoid dosage. These genetic intermediaries provide a direct computational pathway to determine treatment parameters without requiring extensive clinical trial data, thus reducing both time and cost while maintaining precision
2Measurement precision
If traditional trial-and-error methods are used to determine cannabinoid treatment regimens, then treatment efficacy may eventually be achieved, but the cost reaches thousands of dollars
Solution Approach 1:
The patent replaces the mechanical/clinical trial-and-error system with a computational/genetic-based system. Instead of relying on iterative clinical adjustments that consume significant financial resources, the system uses genetic testing and algorithmic calculations to directly determine optimal dosages, dramatically reducing costs while maintaining or improving treatment accuracy
Solution Approach 2:
The patent changes the fundamental parameter used to determine dosage from clinical trial data to genetic profile data. By using SNP genotypes and phenotypic expressions as the basis for dosage calculation, the system transforms an expensive, time-consuming clinical process into a more efficient genetic-based computational process, reducing costs while preserving precision
3Ease of operation
If standardized cannabinoid dosages are used without genetic consideration, then treatment is simpler to implement, but individual genetic variations cause variable and often suboptimal responses
Solution Approach 1:
The patent applies local quality by tailoring the cannabinoid dosage and ratio to each patient's specific genetic profile rather than using a uniform standardized approach. By incorporating individual SNP genotypes and phenotypic expressions into the dosage calculation, the system maintains simplicity of implementation through a standardized genetic-based algorithm while achieving personalized, reliable treatment responses for each patient
4Measurement precision
If genetic testing is performed to determine personalized cannabinoid regimens, then treatment response accuracy is improved, but the complexity of the treatment determination process increases
Solution Approach 1:
The patent segments the complex task of determining optimal cannabinoid dosage into distinct, manageable components: (1) genetic testing to identify SNPs, (2) determining phenotypic expressions from genotypes, (3) calculating dosage based on multiple genetic markers, and (4) establishing the cannabinoid ratio. This segmentation makes the overall complex process more manageable and systematic while achieving high precision through the cumulative effect of multiple genetic parameters
Data Source
AI summary
Methods and systems for providing a personalized cannabinoid treatment regimen to a patient include obtaining genotypes of single nucleotide polymorphisms (SNPs) from a patient's genetic test and modifying base values, such as base dosages or base ratios, using weighting values reflecting the obtained genotypes to obtain regimen values for treating the patient. The regimen values take into account expected responses to cannabinoids based on patient genetic information.